Search Results for: Marc Tessier-Lavigne
The annual recipient of the NY/NJ CEO Lifetime Achievement Award is nominated and elected by peers from within the biotechnology industry and it recognizes the extraordinary contributions of the awardees toward advancing medical science and products that address unmet medical needs, as well as in helping to create an environment that fosters the growth of the industry in the New York metropolitan area.
Congress of the United States U.S. House of Representatives Committee on Science, Space, and Technology Subcommittee on Research and Technology “Policies to Spur Innovative Medical Breakthroughs from Laboratories to Patients” Written Testimony of Dr. Marc Tessier-Lavigne Rayburn House Office Building … More »
Medical innovation requires federal support and structural improvements, Marc Tessier-Lavigne tells members of Congress
Speaking at a hearing on public versus private contributions to medical breakthroughs, Rockefeller’s president explained the ecosystem responsible for taking a biological insight on, for example, how tumors spread, and turning it into a treatment that improves or saves lives. He also offered suggestions for how the federal government could further encourage such breakthroughs.
Tessier-Lavigne, Rockefeller president and head of the Laboratory of Brain Development, and Jeffrey M. Friedman head of the Laboratory of Molecular Genetics, were elected to the honorary society and independent policy research center along with 198 other leaders in science, art, academia and the civic, corporate and philanthropic arenas. The current membership includes some 250 Nobel laureates and more than 60 Pulitzer Prize winners, and 23 other Rockefeller University faculty members are fellows.
President Marc Tessier-Lavigne will receive the Henry G. Friesen International Prize in Health Research, established by the Friends of Canadian Institutes of Health Research in collaboration with the Canadian Academy of Health Sciences to recognize exceptional innovation by a visionary health leader of international stature.
A world leader in the study of brain development, Tessier-Lavigne has pioneered the identification of the molecules that direct the formation of connections among nerve cells to establish neuronal circuits in the mammalian brain and spinal cord. Tessier-Lavigne is among 65 new members and five foreign associates elected to the Institute this year. More »
Rockefeller University’s President will receive the Memorial Sloan-Kettering Medal for Outstanding Contributions to Biomedical Research at MSKCC’s 2011 Academic Convocation. More »
Marc Tessier-Lavigne, a leading neuroscientist and the former chief scientific officer of Genentech, takes over as president of The Rockefeller University today, replacing Paul Nurse, who has left to become president of the Royal Society in London. More »
The university’s Board of Trustees has elected Tessier-Lavigne to succeed Paul Nurse on March 11, 2011. A leader in the study of brain development, he is currently executive vice president for research and chief scientific officer at Genentech, one the world’s leading biotech companies. More »
The award recognizes Fuchs’s contributions to our understanding of skin biology and skin stem cells, including discoveries that have led to advancements in treating skin cancer and severe burns.
Marraffini, who studies the CRISPR-Cas systems that enable some bacteria to acquire immunity against viruses, is among 32 highly qualified young faculty researchers selected to compete for this national award. More »
The Marie-Josée and Henry R. Kravis Foundation provides landmark gift of $100 Million to The Rockefeller University
Marc Tessier-Lavigne, president of The Rockefeller University, today announced a leadership gift of $100 million from The Marie-Josée and Henry R. Kravis Foundation to help create a new laboratory building that will be the centerpiece of the University’s major planned campus extension. More »
Paul Nurse, president emeritus at Rockefeller, has been awarded the Henry G. Friesen International Prize in Health Research. The prize honors him as a pioneering scientist, science advocate, and policy maker who has had an important impact on science through excellence in research, leadership, and communication. More »
Vosshall, who investigates how sensory stimuli are perceived and processed, and Casanova, who studies the genetics of infectious disease susceptibility in children, are among the new members and foreign associates to be inducted into the Academy in 2015. With Vosshall and Casanova’s election, Rockefeller now boasts 36 members or foreign associates of the National Academy of Sciences among its current faculty.
In recognition of her pioneering research on mammalian skin and adult stem cells, Fuchs has received the E.B. Wilson Medal, the highest scientific honor bestowed by the American Society for Cell Biology. The medal will be presented at the society’s annual meeting in California on December 15. More »
The Rockefeller University designated a “Milestones in Microbiology” site by the American Society for Microbiology
The designation is made in recognition of the many outstanding achievements of Rockefeller scientists, and in particular for ground-breaking discoveries by Oswald T. Avery, Colin M. MacLeod, Maclyn McCarty, Peyton Rous, and Emil C. Gotschlich. It will be formally announced at a dedication ceremony on April 8. More »
The rankings, released by the European Commission-funded U-Multirank survey, placed Rockefeller among the top five institutions in five key categories. Across the entire set of rankings, which incorporates data from 1,200 institutions, Rockefeller was the only institution to receive this many top slots.
Considered one of the most prestigious prizes in medicine, the Wolf Prize recognizes Ravetch’s work on the molecular basis of the immune response, including the Fc receptor system that mediates antibody function in disease and health. More »
Experiments show that a protein already implicated in degeneration, called Sarm1, functions to trigger the MAP kinase pathway. Inactivation of this pathway at any of three levels could block the death of damaged axons.